These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32841138)

  • 1. [Familial chylomicronemia].
    Quiroga-Padilla PJ; Gaete PV; Mendivil CO
    Medicina (B Aires); 2020; 80(4):348-358. PubMed ID: 32841138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
    Falko JM
    Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1.
    Ahmad Z; Wilson DP
    J Clin Lipidol; 2014; 8(6):635-639. PubMed ID: 25499947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Diagnosis and Management of Primary Chylomicronemia.
    Okazaki H; Gotoda T; Ogura M; Ishibashi S; Inagaki K; Daida H; Hayashi T; Hori M; Masuda D; Matsuki K; Yokoyama S; Harada-Shiba M
    J Atheroscler Thromb; 2021 Sep; 28(9):883-904. PubMed ID: 33980761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Update on the Chylomicronemia Syndrome.
    Goldberg RB; Chait A
    Front Endocrinol (Lausanne); 2020; 11():593931. PubMed ID: 33193106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
    Chait A; Eckel RH
    Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of therapies for chylomicronemia.
    Shamsudeen I; Hegele RA
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe hypertriglyceridemia : Diagnostics and new treatment principles].
    Kassner U; Dippel M; Steinhagen-Thiessen E
    Internist (Berl); 2017 Aug; 58(8):866-876. PubMed ID: 28516251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.
    Rosenson RS; Gaudet D; Ballantyne CM; Baum SJ; Bergeron J; Kershaw EE; Moriarty PM; Rubba P; Whitcomb DC; Banerjee P; Gewitz A; Gonzaga-Jauregui C; McGinniss J; Ponda MP; Pordy R; Zhao J; Rader DJ
    Nat Med; 2023 Mar; 29(3):729-737. PubMed ID: 36879129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial chylomicronemia syndrome: The first case reported in Ecuador.
    Garay García KJ; Chong Menendez RJ; Nogueira JP; Piedra Andrade JS
    Clin Investig Arterioscler; 2022; 34(6):326-329. PubMed ID: 36184299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.
    Hegele RA; Berberich AJ; Ban MR; Wang J; Digenio A; Alexander VJ; D'Erasmo L; Arca M; Jones A; Bruckert E; Stroes ES; Bergeron J; Civeira F; Witztum JL; Gaudet D
    J Clin Lipidol; 2018; 12(4):920-927.e4. PubMed ID: 29748148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
    Warden BA; Duell PB
    Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chylomicronemia.
    Navarro Hermoso A; Valdivielso P
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():75-79. PubMed ID: 34006359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volanesorsen for treatment of familial chylomicronemia syndrome.
    Lazarte J; Hegele RA
    Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
    Paquette M; Amyot J; Fantino M; Baass A; Bernard S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia.
    Brunzell JD; Bierman EL
    Med Clin North Am; 1982 Mar; 66(2):455-68. PubMed ID: 7040847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
    Esan O; Wierzbicki AS
    Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia.
    Kolovou G; Kolovou V; Katsiki N
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome.
    Rouis M; Dugi KA; Previato L; Patterson AP; Brunzell JD; Brewer HB; Santamarina-Fojo S
    Arterioscler Thromb Vasc Biol; 1997 Jul; 17(7):1400-6. PubMed ID: 9261273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.